Brief: Biofrontera Completes Transfer Of Ameluz® And Rhodoled® FDA Approval
18/12/2025 14:14
Dec 18 (Reuters) - Biofrontera Inc BFRI.O: BIOFRONTERA INC. COMPLETES TRANSFER OF AMELUZ® AND RHODOLED® FDA APPROVAL AND ASSOCIATED INTELLECTUAL PROPERTY PORTFOLIO Source text: ID:nGNX3vSyYL Further company coverage: BFRI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biofrontera
See all newsBrief: Biofrontera Submits Supplemental New Drug Application To FDA To Expand Ameluz® Red Light Pdt To Actinic Keratoses On The Full Body
Biofrontera Inc reports results for the quarter ended June 30 - Earnings Summary
Biofrontera Q2 revenue rises on higher volume, pricing
Biofrontera Inc expected to post a loss of 10 cents a share - Earnings Preview
Biofrontera Q1 revenue rises on higher Ameluz sales